Cargando…
Quality of life assessment in cancer patients receiving single-agent versus multidrug chemotherapy protocols
BACKGROUND: Quality of life (QoL) is an essential factor in therapeutic decision-making for human patients and is commonly used as an endpoint in clinical trials of cancer treatments. AIM: To compare owners’ perception of QoL in canine and feline patients affected by different tumor histotypes treat...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Faculty of Veterinary Medicine
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770191/ https://www.ncbi.nlm.nih.gov/pubmed/35070873 http://dx.doi.org/10.5455/OVJ.2021.v11.i4.28 |
_version_ | 1784635312800006144 |
---|---|
author | Bianchi, Marco Luigi Drudi, Dario Treggiari, Elisabetta Catalucci, Chiara Attorri, Valeria Bonazzi, Irene Valenti, Paola |
author_facet | Bianchi, Marco Luigi Drudi, Dario Treggiari, Elisabetta Catalucci, Chiara Attorri, Valeria Bonazzi, Irene Valenti, Paola |
author_sort | Bianchi, Marco Luigi |
collection | PubMed |
description | BACKGROUND: Quality of life (QoL) is an essential factor in therapeutic decision-making for human patients and is commonly used as an endpoint in clinical trials of cancer treatments. AIM: To compare owners’ perception of QoL in canine and feline patients affected by different tumor histotypes treated with single-agent or multidrug protocols. METHODS: Owners were asked to assess the impact on QoL of their pets undergoing chemotherapy treatment by answering a questionnaire and assigning a score to different health-related parameters reported to affect QoL. RESULTS: Questionnaires of 101 patients (85 dogs and 16 cats), collected at different time points, were analyzed. Fifty-seven patients were given single-agent chemotherapy (carboplatin, doxorubicin, lomustine, melphalan, mitoxantrone, vinblastine, and vinorelbine), whereas 44 were given multiple-agent treatment. When diverse factors including chemotherapy treatment type (single-agent vs. multidrug regimens) and the onset and kind of adverse effects were considered, no significant variations in owners’ perceptions of their pets’ QoL were discovered. CONCLUSION: Chemotherapy type (single-agent vs. multidrug protocol) and related adverse events are shown, which did not influence owners’ perception of their pet’s QoL. Future prospective studies should look into clinical characteristics that might affect QoL, such as the patient’s age, tumor stage, and protocol purpose (curative vs. palliative). |
format | Online Article Text |
id | pubmed-8770191 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Faculty of Veterinary Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-87701912022-01-21 Quality of life assessment in cancer patients receiving single-agent versus multidrug chemotherapy protocols Bianchi, Marco Luigi Drudi, Dario Treggiari, Elisabetta Catalucci, Chiara Attorri, Valeria Bonazzi, Irene Valenti, Paola Open Vet J Original Research BACKGROUND: Quality of life (QoL) is an essential factor in therapeutic decision-making for human patients and is commonly used as an endpoint in clinical trials of cancer treatments. AIM: To compare owners’ perception of QoL in canine and feline patients affected by different tumor histotypes treated with single-agent or multidrug protocols. METHODS: Owners were asked to assess the impact on QoL of their pets undergoing chemotherapy treatment by answering a questionnaire and assigning a score to different health-related parameters reported to affect QoL. RESULTS: Questionnaires of 101 patients (85 dogs and 16 cats), collected at different time points, were analyzed. Fifty-seven patients were given single-agent chemotherapy (carboplatin, doxorubicin, lomustine, melphalan, mitoxantrone, vinblastine, and vinorelbine), whereas 44 were given multiple-agent treatment. When diverse factors including chemotherapy treatment type (single-agent vs. multidrug regimens) and the onset and kind of adverse effects were considered, no significant variations in owners’ perceptions of their pets’ QoL were discovered. CONCLUSION: Chemotherapy type (single-agent vs. multidrug protocol) and related adverse events are shown, which did not influence owners’ perception of their pet’s QoL. Future prospective studies should look into clinical characteristics that might affect QoL, such as the patient’s age, tumor stage, and protocol purpose (curative vs. palliative). Faculty of Veterinary Medicine 2021 2021-12-05 /pmc/articles/PMC8770191/ /pubmed/35070873 http://dx.doi.org/10.5455/OVJ.2021.v11.i4.28 Text en https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Bianchi, Marco Luigi Drudi, Dario Treggiari, Elisabetta Catalucci, Chiara Attorri, Valeria Bonazzi, Irene Valenti, Paola Quality of life assessment in cancer patients receiving single-agent versus multidrug chemotherapy protocols |
title | Quality of life assessment in cancer patients receiving single-agent versus multidrug chemotherapy protocols |
title_full | Quality of life assessment in cancer patients receiving single-agent versus multidrug chemotherapy protocols |
title_fullStr | Quality of life assessment in cancer patients receiving single-agent versus multidrug chemotherapy protocols |
title_full_unstemmed | Quality of life assessment in cancer patients receiving single-agent versus multidrug chemotherapy protocols |
title_short | Quality of life assessment in cancer patients receiving single-agent versus multidrug chemotherapy protocols |
title_sort | quality of life assessment in cancer patients receiving single-agent versus multidrug chemotherapy protocols |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770191/ https://www.ncbi.nlm.nih.gov/pubmed/35070873 http://dx.doi.org/10.5455/OVJ.2021.v11.i4.28 |
work_keys_str_mv | AT bianchimarcoluigi qualityoflifeassessmentincancerpatientsreceivingsingleagentversusmultidrugchemotherapyprotocols AT drudidario qualityoflifeassessmentincancerpatientsreceivingsingleagentversusmultidrugchemotherapyprotocols AT treggiarielisabetta qualityoflifeassessmentincancerpatientsreceivingsingleagentversusmultidrugchemotherapyprotocols AT cataluccichiara qualityoflifeassessmentincancerpatientsreceivingsingleagentversusmultidrugchemotherapyprotocols AT attorrivaleria qualityoflifeassessmentincancerpatientsreceivingsingleagentversusmultidrugchemotherapyprotocols AT bonazziirene qualityoflifeassessmentincancerpatientsreceivingsingleagentversusmultidrugchemotherapyprotocols AT valentipaola qualityoflifeassessmentincancerpatientsreceivingsingleagentversusmultidrugchemotherapyprotocols |